Dongwha Pharm.Co.,Ltd (KRX:000020)

Market Cap	162.43B -6.1%
Revenue (ttm)	496.39B +6.8%
Net Income	8.69B +56.1%
EPS	313.00 +55.7%
Shares Out	27.72M
PE Ratio	18.72
Forward PE	n/a
Dividend	180.00 (3.09%)
Ex-Dividend Date	Mar 24, 2026

Volume	29,287
Average Volume	64,186
Open	5,850.00
Previous Close	5,830.00
Day's Range	5,850.00 - 5,920.00
52-Week Range	5,560.00 - 7,140.00
Beta	0.36
RSI	42.94
Earnings Date	Mar 30, 2026

About Dongwha Pharm.Co.,Ltd

Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health su...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1897
• Employees: 826
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000020

Financial Performance

In 2025, Dongwha Pharm.Co.,Ltd's revenue was 496.39 billion, an increase of 6.78% compared to the previous year's 464.87 billion. Earnings were 8.69 billion, an increase of 56.13%.